Clearside's uveitis therapy clears Phase II hurdle

Clearside Biomedical Inc. (Alpharetta, Ga.) said CLS-TA ( CLS-1001) met the primary endpoint in a Phase II study to treat macular edema associated with non-infectious uveitis. The company said CLS-TA significantly improved central subfield thickness in macular edema patients eight weeks after a single injection (p=0.0018).

The treatment also improved mean best-corrected visual acuity over baseline (p=0.0004), a secondary endpoint. The 22-patient study evaluated 4 mg and 0.8 mg doses of CLS-TA, a triamcinolone acetonide delivered using the company's ocular microinjection platform. CFO Charles Deignan told BioCentury that the study was powered to evaluate only the higher dose. ...